The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.00
Bid: 5.75
Ask: 5.95
Change: -0.525 (-8.24%)
Spread: 0.20 (3.478%)
Open: 6.25
High: 6.25
Low: 6.00
Prev. Close: 6.375
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Positive Developments with Harpin

14 Nov 2018 07:00

RNS Number : 2566H
Plant Health Care PLC
14 November 2018
 

 

 

14 November 2018

PLANT HEALTH CARE plc

 

("Plant Health Care" or the "Company")

 

Positive Developments with Harpin ab in sugarcane in Brazil

 

Plant Health Care®, a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to provide the following update on the launch of H2Copla (Harpin ab) in sugarcane in Brazil.

 

Highlights:

- H2Copla (Harpin ab) has been applied on some 20,000 hectares (Ha) of sugarcane since 'soft launch' in February 2018

- Average yield increases in excess of 20% are driving strong demand; early adopters plan to switch entirely to H2Copla for the next season

- Grower response to the results has been very positive

- Sales by PHC to Coplacana are expected to reach $0.8m in 2018, pointing to strong growth in 2019

 

As previously announced, Brazil sugarcane, with 10 million Ha planted, is an important target for Plant Health Care. The Company has been developing Harpin ab for use in this crop since 2016. Coplacana, a very large co-operative and the leading distributor of inputs for sugarcane, was appointed as distributor to launch Harpin ab under the brand name H2Copla. Following a 'soft launch' in February 2018, Coplacana has been carrying out extensive demonstration trials of the product; H2Copla has been applied on some 20,000 Ha to date by various growers.

 

Trials conducted on behalf of the Company in 2018 showed that single applications of a low dose (100 g per Ha), significantly increased the yield of sugarcane (10-29%). Moreover, it is possible that the life of the crop may be extended from five to six years, resulting in a material cost reduction for the grower, especially when sugar prices are low. Grower response to the results has been very positive.

 

Furthermore Usina Açucareira Furlan S/A ('Furlan'), a large sugarcane producer located in the state of São Paulo, carried out field trials in 2018, as part of the soft launch by Coplacana, which delivered an average 23% yield increase from H2Copla applicatons. Furlan now plans to use H2Copla on their entire area next season.

 

Gilmar Rorigues de Morais, Agriculture Department Manager at Furlan, said "We are excited about the yield increases from this year's trials and plan to use H2Copla on all of our 20,000 Ha for the 2019 growing season."

 

Chris Richards, Executive Chairman and Interim CEO of Plant Health Care, noted: "Grower reaction to demonstration trials of H2Copla has been very positive. Growers have already treated some 20,000 Ha of sugarcane with the product. The indication that just one customer (Furlan) plans to use H2Copla on 20,000 Ha next year, points to significant revenue growth in 2019. Demand for Harpin ab in Brazil is expected to reach at least $0.8m in 2018."

For further information, please contact:

 

Plant Health Care plc

Chris Richards, Executive Chairman and Interim CEO Tel: +1 919 926 1600

Jeff Tweedy, COO

 

Arden Partners plc - Nomad and BrokerJohn Llewellyn-Lloyd / Dan Gee-Summons Tel: +44 (0) 20 7614 5900

 

IFC Advisory - Financial PR

Graham Herring / Miles Nolan / Zach Cohen Tel: +44 (0) 20 3934 6633

 

 

Company website: www.planthealthcare.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDUOUWRWSAAAAA
Date   Source Headline
1st Sep 20217:00 amRNSArgentina approves Harpin as a seed treatment
24th Aug 20217:00 amRNSInvestor Presentation
18th Aug 20214:41 pmRNSSecond Price Monitoring Extn
18th Aug 20214:36 pmRNSPrice Monitoring Extension
9th Aug 20211:27 pmRNSHolding(s) in Company
3rd Aug 20217:00 amRNSAdmission to the U.S. OTCQB Venture Market
27th Jul 20217:00 amRNSNew Distribution Agreement with Agrii UK
26th Jul 20217:00 amRNS2021 Half-Year Trading Statement
23rd Jul 20217:00 amRNSGrant of Options
22nd Jul 20217:00 amRNSInvestor Presentation
12th Jul 20214:40 pmRNSSecond Price Monitoring Extn
12th Jul 20214:35 pmRNSPrice Monitoring Extension
29th Jun 20214:41 pmRNSSecond Price Monitoring Extn
29th Jun 20214:35 pmRNSPrice Monitoring Extension
14th Jun 20212:33 pmRNSResult of AGM
14th Jun 20217:00 amRNSGreen Economy Mark awarded
9th Jun 20214:41 pmRNSSecond Price Monitoring Extn
9th Jun 20214:35 pmRNSPrice Monitoring Extension
20th May 20217:00 amRNSInvestor Presentation
7th May 20213:50 pmRNSAnnual Report & Accounts and AGM Notice Published
30th Apr 20215:40 pmRNSHolding(s) in Company
23rd Apr 20217:00 amRNSResults for the year ended 31 December 2020
21st Apr 202111:58 amRNSHolding(s) in Company
8th Apr 20213:30 pmRNSHolding(s) in Company
1st Apr 20217:00 amRNSTotal Voting Rights
22nd Mar 20217:00 amRNSInvestor Presentation
18th Mar 20211:57 pmRNSResults of Placing and Subscription
18th Mar 20217:00 amRNSProposed Placing and Subscription
1st Mar 20217:00 amRNSSaori Trial Update
3rd Feb 20214:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20214:36 pmRNSPrice Monitoring Extension
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:36 pmRNSPrice Monitoring Extension
25th Jan 20217:00 amRNSTrading Statement
11th Jan 20217:00 amRNSNotice of Trading Statement/Investor Presentation
5th Jan 20213:37 pmRNSBrazil approves PHC279 to Control Soybean Rust
11th Dec 20207:00 amRNSInvestor Presentation
9th Nov 20207:00 amRNSPlant Health Care and Wilbur-Ellis sign Agreement
7th Oct 20207:00 amRNSGrant of Options
6th Oct 20207:00 amRNSNew US PREtec Patents Issued
2nd Oct 20205:48 pmRNSSignificant Shareholder
25th Sep 20207:00 amRNSInvestor Presentation
23rd Sep 20207:00 amRNSInvestor Presentation
15th Sep 20207:00 amRNSInterim Report 30 June 2020
29th Jul 20207:00 amRNSTrading Statement
26th Jun 20204:41 pmRNSSecond Price Monitoring Extn
26th Jun 20204:36 pmRNSPrice Monitoring Extension
25th Jun 20207:00 amRNSGrant of Options
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.